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Summary
Seven Angus-cross steers (475 lbs initial
body weight) were used in a 7 × 4 incomplete
Latin square experiment to evaluate the effects
of supplemental L-carnitine on nitrogen balance
and blood metabolites.  Steers were fed the
same high-protein, corn-based diet near ad
libitum intake.  Treatments were  control and
.25, .5, 1.0, 1.5, 2.0, and 3.0 grams/day of
supplemental carnitine.  Experimental periods
were 18 days with 13 days for adaptation and
5 days for collection of feces and urine.  Blood
was collected at feeding and 3 and 6 hours after
feeding on day 18 of each period.  Supplement-
ing steers with carnitine increased urinary carni-
tine excretion and plasma carnitine concentra-
tion.  Nitrogen retention (a measure of protein
deposition) was not affected by carnitine
supplementation and averaged 29.3 g/d.
Plasma insulin and glucagon, indicative of energy
status, and cholesterol and triglyceride, repre-
sentative of energy storage metabolites, were
not affected by carnitine supplementation.
Plasma glycerol and beta-hydroxybutyrate,
reflective of fat catabolism, increased with
intermediate levels of supplemental carnitine.  In
conclusion, carnitine supplementation did not
alter N balance in our experiment, but it did alter
some of the plasma metabolites of steers fed
high-protein, corn-based diets.
(Key Words: Growing Steers, Carnitine, Nitro-
gen Balance, Plasma Metabolites.) 
Introduction
Newly weaned calves generally are limit-fed
high-energy (corn-based) diets or fed low-
energy (forage-based) diets ad libitum to 
restrict growth before they enter the finishing
phase.  These dietary regimens are implemented
to increase the proportion of gain that is lean
and decrease the proportion that is fat.  Al-
though this restricted growth optimizes finishing
performance, it lengthens the time cattle must be
fed to achieve market weight. 
Carnitine is a vitamin-like compound re-
quired to metabolize fat for energy.  It can either
be produced by the body (de novo) or ab-
sorbed from the diet.  However, negligible
amounts of carnitine are found in common
feedstuffs.  Supplemental carnitine potentially
could serve as a repartitioning agent by increas-
ing fat utilization for energy, thereby increasing
lean gain at the expense of fat deposition.  This
would allow growing cattle to be given ad
libitum access to high-energy diets without
causing excessive fat deposition, which would
reduce the days required for cattle to achieve
market weights.  Our objectives were to evalu-
ate the effects of supplemental L-carnitine on
nitrogen balance and key blood metabolites.
Experimental Procedures
 Seven Angus-cross steers (475 lbs initial
body weight) were used in a 7 × 4 incomplete
Latin square design with seven treatments and
four periods.  Experimental periods were 18
days with 13 days for adaptation and 5 days for
collection of feces and urine.  Steers were
housed in metabolism crates and fed a high-
protein, corn-based diet at 2.5% of BW daily
(Table 1).
 Treatments were control and .25, .5, 1.0,
1.5, 2.0, and 3.0 grams/ day of supplemental
carnitine provided as Carniking® (Lonza).
Blood was collected at feeding and 3 and 6 
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hours after feeding on day 18 of each period.
Only three observations were obtained for .25
grams carnitine/ day.
Table 1. Composition of the Basal Dietab
Ingredient % of Dry Matter
Rolled corn 71.9
Alfalfa 10.0
Blood meal 4.0
Corn gluten meal 4.0
Molasses 4.0
Soybean meal 2.1
Tallow 1.6
Urea .4
Minerals/vitamins 2.0
aDiet contained (dry matter basis): Ca .75%, P
.35%, Mg .20%, K .70%, Na .17%, S .20%,
Cl .45%, vitamin A 1.16 KIU/lb, monensin 29
g/ton, tylosin 9.7 g/ton.
bAdded to diet (dry matter basis): Co .03 ppm,
Cu 8.1 ppm, I .41 ppm, Fe 132 ppm, Mn 40
ppm, Se .23 ppm, 
Zn 41 ppm.
 
Results and Discussion
Supplementing steers with carnitine in-
creased (P<.01) urinary carnitine excretions
(Table 2) and tended to increase (P<.07) plas-
ma carnitine concentrations (Table 3), illustrating
that at least a portion of the dietary carnitine was
absorbed.  Urinary carnitine excretion was
increased notably when 2.0 and 3.0 grams/day
of carnitine were fed. 
Nitrogen retention, a measure of protein
deposition, averaged 29.3 grams/day and was
not affected by carnitine supplementation.  This
indicates that de novo and basal dietary carnitine
supplies were adequate to meet the animals’
requirements for maximal protein gain.  Addi-
tionally, plasma urea nitrogen, reflective of
protein catabolism, and alpha-amino nitrogen,
reflective of circulating amino acids, were not
affected by carnitine supplementation (Table 3).
Concentrations of plasma metabolites repre-
sentative of energy status generally were not
affected by carnitine supplementation.  Insulin
averaged 1.72 ng/ml; glucagon, 199.9 pg/ml;
insulin-like growth factor-1, 264.3 ng/ml; cho-
lesterol, 141.9 mg/dl; and triglycerides, 16.0
mg/dl.  A significant cubic increase (P<.02) in
glucose concentrations occurred, but this did not
correspond to changes in insulin, which generally
responds to glucose levels.  Metabolites reflec-
tive of lipid metabolism increased with interme-
diate levels of carnitine.  Plasma glycerol
(P<.04) and beta-hydroxybutyrate (P<.14)
increased when 1.0 to 2.0 grams/day of
carnitine were fed.  Plasma nonesterified fatty
acids measured before feeding decreased lin-
early (108.7 to 92.7 meq/L) with increasing
carnitine supplementation, but they increased
linearly (95.4 to 109.3 meq/L) at 6 hours
postfeeding (data not shown).  This may indicate
that as steers were provided more carnitine, less
adipose was catabolized prefeeding, whereas
more circulating lipids were metabolized post-
feeding.  
In conclusion, carnitine supplementation did
not increase nitrogen retention but did alter
some blood and plasma metabolites.  Although
supplementation might affect lipid metabolism,
the inability of carnitine to alter hormone con-
centrations or protein deposition raises ques-
tions about the importance of  alterations in
these factors. 
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Table 2. Effects of Carnitine Supplementation on Nitrogen Balance and Urinary Carnitine Excretion
Carnitine (grams/day) Contrast (P=)a
Item 0 .25 .50 1.0 1.5 2.0 3.0 SEMb L Q C
nc 4 3 4 4 4 4 4
Nitrogen
Intake, g/day 165.4 167.3 153.7 167.9 174.3 170.2 158.0 5.5 .96 .12 .14
Feces, g/day 36.4 34.3 33.4 35.7 37.7 36.9 35.5 1.1 .32 .31 .07
Urine, g/day 96.5 108.8 94.6 99.9 103.2 102.4 96.5 5.1 .78 .47 .70
Retention, g/day 32.4 24.1 25.7 32.3 33.5 31.0 26.1 3.4 .99 .21 .22
Digestibility, % 77.9 79.5 78.4 79.0 78.4 78.1 77.6 .76 .31 .47 .49
Urine carnitine, mg/d 46 62 30 90 119 180 428 31.8 .001 .003 .66
aL= linear, Q= quadratic, C= cubic.
bFor n= 4.
cn= number of observations per treatment.
Table 3.  Effects of Carnitine Supplementation on Plasma and Blood Metabolites 
Carnitine (grams/day) Contrast (P=)a
Item 0 .25 .50 1.0 1.5 2.0 3.0 SEMb L Q C
nc 4 3 4 4 4 4 4
Plasma
Carnitine, nmol/ml 58 54 75 65 74 82 79 9.8 .07 .46 .92
Insulin, ng/ml 1.59 1.94 1.49 1.70 1.83 1.70 1.77 .26 .75 .97 .98
Glucagon, pg/ml 195 204 184 198 192 217 209 17 .38 .86 .50
IGF-1d, ng/ml 271 252 251 243 267 274 292 34 .42 .57 .61
Glucose, mM 5.06 5.21 5.28 5.22 5.26 5.06 5.34 .08 .28 .83 .02
Cholesterol, mg/dl 141 127 130 151 157 145 142 10 .31 .22 .58
Triglyceride, mg/dl 15.1 16.5 15.5 17.1 14.9 17.1 16.1 .88 .56 .56 .82
Glycerol, mg/dl .97 .31 1.24 1.01 1.57 1.73 .48 .40 .74 .04 .19
NEFAd, meq/L 101.9 97.3 105.1 107.6 103.2 97.4 101.4 3.7 .76 .53 .19
Urea, mM 5.20 5.34 5.07 5.51 5.48 5.40 5.07 .20 .90 .12 .66
µ-amino N, mM 2.84 2.67 2.66 2.84 2.85 2.95 2.81 .15 .43 .63 .30
Blood
BHBAd, mM .181 .192 .161 .196 .237 .210 .182 .023 .48 .14 .33
These values represent the means across the three sampling times (at feeding and 3 and 6 hours after feeding).
Except for NEFA, no significant treatment × time interactions were observed.
aL= linear, Q= quadratic, C= cubic.
bFor n= 4.
cn= number of observations per treatment.
dIGF-1= insulin-like growth factor-1; NEFA= non-esterified fatty acid; BHBA= beta-hydroxbutyrate.
